The DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls
Open accessAbstract
Case-control studies are commonly used to evaluate effectiveness of licensed vaccines after deployment in public health programs. Such studies can provide policy-relevant data on vaccine performance under 'real world' conditions, contributing to the evidence base to support and sustain introduction of new vaccines. However, case-control studies do not measure the impact of vaccine introduction on disease at a population level, and are subject to bias and confounding, which may lead to inaccurate results that can misinform policy decisions. In 2012, a group of experts met to review recent experience with case-control studies evaluating the effectiveness of several vaccines; here we summarize the recommendations of that group regarding best practices for planning, design and enrollment of cases and controls. Rigorous planning and preparation should focus on understanding the study context including healthcare-seeking and vaccination practices. Case-control vaccine effectiveness studies are best carried out soon after vaccine introduction because high coverage creates strong potential for confounding. Endpoints specific to the vaccine target are preferable to non-specific clinical syndromes since the proportion of non-specific outcomes preventable through vaccination may vary over time and place, leading to potentially confusing results. Controls should be representative of the source population from which cases arise, and are generally recruited from the community or health facilities where cases are enrolled. Matching of controls to cases for potential confounding factors is commonly used, although should be reserved for a limited number of key variables believed to be linked to both vaccination and disease. Case-control vaccine effectiveness studies can provide information useful to guide policy decisions and vaccine development, however rigorous preparation and design is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Vaccine effectiveness was estimated using the test-negative, case–control study design11,12, applying methodology that was developed earlier to assess duration of protection of the BNT162b213 and mRNA-127314 vaccines in the same population during pre-Omicron SARS-CoV-2 infection waves (Methods).”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [12]
In the citing paper
“Vaccine effectiveness against symptomatic SARS-CoV-2 Omicron (B.1.1.529)1 infection during the large Omicron wave in Qatar, between December 23, 2021 and February 28, 2022, was estimated using the test-negative, case–control study design, a standard design for assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [12]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Epidemiology 3rd edition
Rothman, K. J., Lash, T. L., & Greenland, S. (1986) · Cited by 1,736
Serotype replacement in disease after pneumococcal vaccination
Weinberger, D. M., Malley, R., & Lipsitch, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62225-8 · Cited by 1,027 · cited 1×
“For pneumococcal conjugate vaccines, this assumption may not be valid, since their widespread use has been associated with increases in non-vaccine type pneumococcal carriage and disease incidence [80].”
BackgroundSelection of Controls in Case-Control Studies
Wacholder, S., McLaughlin, J. K., Silverman, D. T., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116396 · Cited by 998
Herd Immunity: History, Theory, Practice
Fine, P. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036121 · Cited by 906 · cited 1×
“vaccination of part of the population leading to reduced transmission of the infection in the community, and thus lowered risk of disease in both vaccinated and unvaccinated persons) [8].”
BackgroundSelection of Controls in Case-Control Studies: II. Types of Controls
Wacholder, S., Silverman, D. T., McLaughlin, J. K., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116397 · Cited by 624 · cited 5×
“confounding), since unnecessary matching can lead to reduced efficiency in the analysis and substantially increases the complexity of study implementation [65,82,84].”
BackgroundInfluentialWhitney, C. G., Pilishvili, T., Farley, M. M., Schaffner, W., Craig, A. S., Lynfield, R., Nyquist, A., Gershman, K. A., Vázquez, M., Bennett, N. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69637-2 · Cited by 623
Self-citationVaccines for preventing influenza in healthy children
Jefferson, T., Rivetti, A., Pietrantonj, C. D., Demicheli, V., & Ferroni, E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004879.pub4 · Cited by 551
Field evaluation of vaccine efficacy.
Orenstein, W. A., Bernier, R. H., Tj, D., Hinman, A. R., Js, M., Bart, K. J., & Sirotkin, B. (1985) · Europe PMC (PubMed Central) · Cited by 549
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Compared to what? Finding controls for case-control studies.
Grimes, D., & Schulz, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66379-9 · Cited by 431 · cited 8×
“Children hospitalized with vaccine-preventable diseases should be excluded as controls, as they are probably less likely to be vaccinated in general, including with the vaccine under study [51,62].”
BackgroundInfluential
Research works printed but not linked: 4
- Domingues, 2014, Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study, Lancet Respirat Med, 2, 464, 10.1016/S2213-2600(14)70060-8 · DOI
- Baqui, 2007, Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study, Pediatr Infect Dis J, 26, 565, 10.1097/INF.0b013e31806166a0 · DOI
- de la Hoz, 2004, Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia, Vaccine, 23, 36, 10.1016/j.vaccine.2004.05.017 · DOI
- Rothman KJ, Greenland S, Lash TL. Modern epidemiology, 3rd edition. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. p. 168–82.
Cited by
Sorted by citations
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Looking beyond COVID-19 vaccine phase 3 trials
Kim, J. H., Marks, F., & Clemens, J. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01230-y · Cited by 601
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
“2 Omicron infection Effectiveness against any symptomatic Omicron infection Cases* (PCR-positive) Controls* (PCR-negative) SMD† Cases* (PCR-positive) Controls* (PCR-negative) SMD† Cases* (PCR-positive) Controls* (PCR-negative) SMD† N= 3,212 N= 3,212 N=10,646 N=10,646 N=13,139 N=13,139 Median age (IQR) — years 30 (15-3…”
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2200133 · Cited by 445
Metadata
- Authors
- Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., Madhi, S. A., Mulholland, K., O'Brien, K. L., Parashar, U. D., Patel, M. M., Rodrigues, L. C., Santosham, M., Scott, J. A., Smith, P. G., Sommerfelt, H., Tate, J. E., Victor, J. C., Whitney, C. G., Zaidi, A. K., & Zell, E. R.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Johns Hopkins University (US)
- Emory University (US)
- World Health Organization (CH)
- National Institute for Communicable Diseases (ZA)
- University of the Witwatersrand (ZA)
- Gavi (CH)
- Royal Children's Hospital (AU)
- London School of Hygiene & Tropical Medicine (GB)
- Kenya Medical Research Institute (KE)
- Norwegian Institute of Public Health (NO)
- Aga Khan University (PK)
- Corresponding author
- Verani, Jennifer R.
- ORCID
- Verani, Jennifer R.
- Baqui, Abdullah H.
- Cherian, Thomas
- Cohen, Cheryl
- Farrar, Jennifer L.
- Feikin, Daniel R.
- Groome, Michelle J.
- Hajjeh, Rana A.
- Johnson, Hope L.
- Madhi, Shabir A.
- Mulholland, Kim
- Parashar, Umesh D.
- Patel, Manish M.
- Rodrigues, Laura C.
- Scott, J. Anthony
- Smith, Peter G.
- Sommerfelt, Halvor
- Tate, Jacqueline E.
- Victor, J. Chris
- Whitney, Cynthia G.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 35
- Issue
- 25
- Pages
- 3295-3302
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC7007298
- OpenAlex
- W2605758023
- Cited by
- 102
- References
- 82
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 9 · 2023: 17 · 2022: 22 · 2021: 14 · 2020: 7 · 2019: 10 · 2018: 3
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Vaccine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-nd)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- GAVI Alliance
- World Health Organization
- Wellcome Trust (098532/B/12/Z, 203077)
- Centers for Disease Control and Prevention (U01IP001048)
- Medical Research Council (MR/K012126/1)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- vaccine effectiveness, case-control study, research design, confounding, vaccine introduction, health-seeking behavior, vaccination practices
- MeSH terms
- Immunogenicity, Vaccine, Female, Humans, Male, Vaccination, Vaccines, Case-Control Studies, Treatment Outcome, Immunization Programs, Control Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
